AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 5.42 |
Market Cap | 198.32M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.06 |
PE Ratio (ttm) | -2.61 |
Forward PE | n/a |
Analyst | Hold |
Ask | 6.19 |
Volume | 5,938 |
Avg. Volume (20D) | 24,862 |
Open | 5.49 |
Previous Close | 5.48 |
Day's Range | 5.38 - 5.50 |
52-Week Range | 3.32 - 12.70 |
Beta | undefined |
About MOLN
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for th...
Analyst Forecast
According to 1 analyst ratings, the average rating for MOLN stock is "Hold." The 12-month stock price forecast is $4.5, which is a decrease of -16.36% from the latest price.